TY - JOUR
T1 - Anti-Müllerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy
AU - Iwase, Akira
AU - Sugita, Atsuko
AU - Hirokawa, Wakana
AU - Goto, Maki
AU - Nakahara, Tatsuo
AU - Kajiyama, Hiroaki
AU - Shibata, Kiyosumi
AU - Nagatomo, Yoshinari
AU - Kikkawa, Fumitaka
PY - 2013/4
Y1 - 2013/4
N2 - With proper and careful selection of patients, fertility-preserving surgery may be feasible in patients with ovarian malignancies. However, the loss of follicles by oophorectomy and chemotherapy results in decreased ovarian reserve, which consecutively affects reproductive capacity. We evaluated postoperative levels of serum anti-Müllerian hormone (AMH) in women with ovarian malignancies to assess the impact of the fertility-preserving surgery with or without the administration of chemotherapy on ovarian reserve. In 13 patients who underwent the fertility-preserving surgery with (n = 9) or without (n = 4) the administration of chemotherapy, serum AMH levels were measured and compared with serum AMH levels measured in patients undergone cystectomy for benign ovarian tumors as a control. We found that the mean AMH level in the treatment group measured 0.9 ng/mL, which was significantly lower than that measured in the control group (4.70 ± 3.77 ng/mL). The possibility of decreased ovarian reserve occurring in patients with ovarian malignancies following treatment with fertility-preserving surgery with or without the administration of chemotherapy should be considered for fertility planning.
AB - With proper and careful selection of patients, fertility-preserving surgery may be feasible in patients with ovarian malignancies. However, the loss of follicles by oophorectomy and chemotherapy results in decreased ovarian reserve, which consecutively affects reproductive capacity. We evaluated postoperative levels of serum anti-Müllerian hormone (AMH) in women with ovarian malignancies to assess the impact of the fertility-preserving surgery with or without the administration of chemotherapy on ovarian reserve. In 13 patients who underwent the fertility-preserving surgery with (n = 9) or without (n = 4) the administration of chemotherapy, serum AMH levels were measured and compared with serum AMH levels measured in patients undergone cystectomy for benign ovarian tumors as a control. We found that the mean AMH level in the treatment group measured 0.9 ng/mL, which was significantly lower than that measured in the control group (4.70 ± 3.77 ng/mL). The possibility of decreased ovarian reserve occurring in patients with ovarian malignancies following treatment with fertility-preserving surgery with or without the administration of chemotherapy should be considered for fertility planning.
UR - http://www.scopus.com/inward/record.url?scp=84883138030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883138030&partnerID=8YFLogxK
U2 - 10.3109/09513590.2012.743008
DO - 10.3109/09513590.2012.743008
M3 - Article
C2 - 23305483
AN - SCOPUS:84883138030
SN - 0951-3590
VL - 29
SP - 357
EP - 360
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
IS - 4
ER -